Healthy volunteers test experimental drug for future clot prevention
NCT ID NCT06669234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety of an experimental drug, ALN-F1202, in 56 healthy adults. The drug aims to lower a clotting factor, but this trial only checks for side effects and how the body processes the drug. Participants receive a single dose and are monitored closely. There is no direct health benefit for volunteers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)
Leuven, Vlaams-Brabant, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?